France Phenylketonuria Market Size & Outlook, 2026-2034
France Phenylketonuria Market Insights
- According to Reed Intelligence analysis, the France Phenylketonuria Market size was USD 50.19 Million in 2025 and is projected to reach USD 90.29 Million by 2034.
- The France market is projected to grow at a CAGR of 6.71% between 2026 and 2034.
- By segment, Enzyme Replacement Therapy emerged as the largest By Treatment Type in terms of market size in 2025.
- Gene Therapy is anticipated to remain the most attractive By Treatment Type segment, recording the fastest growth during the forecast period.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- France accounted for 3.8% of the global Phenylketonuria Market size in 2025.
- By 2034, United States is expected to remain the top global market in terms of size.
- Within Europe, Germany is forecasted to dominate the regional Phenylketonuria Market size by 2034.
- Germany will be the fastest-growing market in Europe, projected to achieve USD 128.35 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 50.19 Million |
| Market Size In 2034 | USD 90.29 Million |
| Largest segment | Enzyme Replacement Therapy |
| Units | Revenue in USD Million |
| CAGR | 6.71% (2026-2034) |
| Segmnetation Covered | |
| By Treatment Type |
|
| By Diagnosis |
|
| By End-User |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
France Phenylketonuria Market By Treatment Type 2026-2034 (USD Million)
| By Treatment Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Enzyme Replacement Therapy | XX.x | XX.x | XX.x | 20.42 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Gene Therapy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Medication | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Dietary Therapy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
France Phenylketonuria Market By Diagnosis 2026-2034 (USD Million)
| By Diagnosis | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genetic Testing | XX.x | XX.x | XX.x | 23.52 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Biochemical Testing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Newborn Screening | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
France Phenylketonuria Market By End-User 2026-2034 (USD Million)
| By End-User | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specialty Clinics | XX.x | XX.x | XX.x | 20.18 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Research Institutes | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Home Healthcare | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Hospitals | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.